SIGY · Sigyn Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These matters raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Total shares sold short and not yet covered, reported to FINRA by broker-dealers twice a month. Each reading settles on the 15th and the last business day of the month and is published seven business days later — the next scheduled dates are listed at the top of the table. Days to cover divides the short position by average daily volume; a high value (above 5) can signal short-squeeze potential.
Peer-relative percentile rank across all stocks reporting short interest at the latest settlement date (2026-07-15). Weighted mean of the available factors (short interest 30%, days to cover 20%, price vs VWAP 15%, short-volume trend 15%, short-interest change 10%, fails-to-deliver 10%) plus catalyst boosts (price spike, volume surge, earnings within days), capped at +20 and clamped to 100.
Short Interest History
| Settlement Date | Current Position | Previous Position | Change | Days to Cover |
|---|---|---|---|---|
|
2026-08-14
Scheduled
FINRA publishes Aug 25
|
— | — | — | — |
|
2026-07-31
Scheduled
FINRA publishes Aug 11
|
— | — | — | — |
| 2026-07-15 | 1,501 | 7,095 | -5,594 | 1.00 |
| 2026-06-30 | 7,095 | 15,577 | -8,482 | 1.00 |
| 2026-06-15 | 15,577 | 32,362 | -16,785 | 1.00 |
| 2026-05-29 | 32,362 | 2,735 | +29,627 | 1.00 |
| 2026-05-15 | 2,735 | 20,045 | -17,310 | 1.00 |
| 2026-04-30 | 20,045 | 2,635 | +17,410 | 1.00 |
| 2026-04-15 | 2,635 | 2,635 | 0 | 1.00 |
| 2026-03-31 | 2,635 | 29,321 | -26,686 | 1.00 |
| 2026-03-13 | 29,321 | 95 | +29,226 | 1.00 |
| 2026-02-27 | 95 | 95 | 0 | 1.00 |
| 2026-02-13 | 95 | 95 | 0 | 1.00 |
| 2026-01-30 | 95 | 275 | -180 | 1.00 |
| 2026-01-15 | 275 | 90 | +185 | 1.00 |
| 2025-12-31 | 90 | 100 | -10 | 1.17 |
| 2025-12-15 | 100 | 70 | +30 | 1.00 |
| 2025-11-28 | 70 | 0 | +70 | 1.00 |